Q4 2018

Source filing unavailable

Q4 2018 · —

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$3.47M

derivedno prior Q4 2017 on file

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Incomederived-$3,842,000—

Operating Cash Flowderived

Same quarter

no prior Q4 2017 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR